Viatris Inc (VTRS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Viatris Inc Stock (VTRS) Company Profile

Healthcare (1109)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

Prossima data di guadagno

Ultimi documenti SEC

VTRS's Discussions on Twitter

Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VTRS Viatris Inc	16.48	19.19B	14.57B	-296.50M	1.64B	-0.259
TAK Takeda Pharmaceutical Co Adr	15.91	50.27B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	34.63	40.32B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.13	40.31B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	79.57	33.36B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	545.96	23.17B	3.17B	1.29B	1.01B	27.09

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-09	Aggiornamento	UBS	Neutral → Buy
2026-01-16	Aggiornamento	Argus	Hold → Buy
2025-12-09	Iniziato	Barclays	Overweight
2025-10-15	Iniziato	Truist	Buy
2025-06-06	Iniziato	Goldman	Neutral
2024-07-19	Ripresa	Jefferies	Buy
2023-10-23	Downgrade	BofA Securities	Neutral → Underperform
2023-06-23	Downgrade	Barclays	Equal Weight → Underweight
2023-04-24	Downgrade	Barclays	Overweight → Equal Weight
2023-02-17	Downgrade	BMO Capital Markets	Outperform → Market Perform
2023-01-27	Aggiornamento	Jefferies	Hold → Buy
2022-11-10	Aggiornamento	UBS	Sell → Neutral
2022-11-08	Aggiornamento	Piper Sandler	Underweight → Neutral
2022-10-21	Ripresa	Jefferies	Hold
2022-06-14	Iniziato	UBS	Sell
2022-05-10	Downgrade	Piper Sandler	Neutral → Underweight
2022-03-01	Downgrade	BofA Securities	Buy → Neutral
2022-03-01	Downgrade	Raymond James	Outperform → Mkt Perform
2021-06-15	Iniziato	Citigroup	Neutral
2021-04-07	Ripresa	RBC Capital Mkts	Outperform
2021-03-08	Downgrade	Goldman	Buy → Neutral
2021-03-02	Downgrade	JP Morgan	Overweight → Neutral
2021-02-26	Downgrade	Wolfe Research	Outperform → Peer Perform
2021-01-05	Iniziato	Argus	Hold
2020-12-14	Iniziato	Bernstein	Mkt Perform

Mostra tutto

Viatris Inc Borsa (VTRS) Ultime notizie

Viatris Inc Azioni (VTRS) Dati Finanziari

Viatris Inc (VTRS)

Viatris Inc Stock (VTRS) Company Profile

Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Viatris Inc Borsa (VTRS) Ultime notizie

Viatris Inc. stock rises Friday, outperforms market - MarketWatch

[424B5] Viatris Inc Prospectus Supplement (Debt Securities) - Stock Titan

A Look at Viatris Inc (VTRS) After 3.4% Gain -- GF Value $11.01 vs Price $16.31 - GuruFocus

VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill

Viatris Inc. stock rises Thursday, outperforms market - MarketWatch

Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch

Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch

Viatris Inc. (VTRS) Stock Analysis: Exploring a 13.70% Potential Upside with a Strong Dividend Yield - DirectorsTalk Interviews

Viatris (VTRS) Holds Steady Near Support Amid Flat Trading SessionRSI Overbought Alerts - newsline.com

Liquidity Mapping Around (VTRS) Price Events - Stock Traders Daily

FDA accepts Viatris' NDA for fast-acting non-opioid pain therapy - MSN

Investors brace for Viatris earnings as CFO departure looms By Investing.com - Investing.com Nigeria

Here's Why Viatris (VTRS) is a Strong Value Stock - Yahoo Finance

Salesforce : Agentforce Life Sciences Selected by Viatris as Its Global Customer Engagement Platform - marketscreener.com

Viatris Inc. stock falls Monday, underperforms market - MarketWatch

Viatris Inc. (VTRS) Stock Analysis: Exploring An 11% Potential Upside Amid Mixed Metrics - DirectorsTalk Interviews

Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune

Does FDA Review of Fast-Acting Meloxicam Shift Viatris’ (VTRS) Non-Opioid Pain Strategy? - simplywall.st

Viatris Inc. stock falls Thursday, underperforms market - MarketWatch

Viatris Top Brass Sued by Investor Over India Facility Problems - Bloomberg Law News

Argus Raises Viatris Price Target to $18 From $15 - Moomoo

Why (VTRS) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Analyst Report Highlights Viatris Inc’s Strategic Positioning Amid Generic Drug CompetitionLow Estimate Range - newsline.com

Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch

Viatris (VTRS) Under Pressure: Support Levels Tested After 1.5% DeclineVolatility Smile - newsline.com

Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035 - GlobeNewswire Inc.

Viatris Inc. (VTRS) Stock Analysis: Investor Outlook on a Healthcare Giant with an 8.44% Upside Potential - DirectorsTalk Interviews

Assessing Viatris (VTRS) Valuation After FDA Review Acceptance For Fast Acting Non Opioid Meloxicam - Yahoo Finance

What Viatris (VTRS)'s Fast-Acting Pain Drug Filing and Profit Uptick Means For Shareholders - simplywall.st

Viatris Inc.: - marketscreener.com

Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance

Viatris (VTRS) price target increased by 10.47% to 17.48 - MSN

Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch

VTRS Maintains Overweight Rating -- Price Target Raised to $22 - GuruFocus

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy - Yahoo! Finance Canada

Viatris CFO leaving Canonsburg pharma giant - MSN

Barclays Adjusts Price Target on Viatris to $22 From $17, Maintains Overweight Rating - Moomoo

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain - Sahm

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Me - GuruFocus

TrumpRx expands into generic medicines (VTRS:NASDAQ) - Seeking Alpha

Viatris rises as Q1 beat indicates growth momentum - MSN

Viatris' Acute Pain Drug NDA Accepted for Review by FDA - Moomoo

5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call - Yahoo Finance

Here's Why Viatris (VTRS) is a Strong Momentum Stock - Yahoo Finance

U.S. FDA accepts Viatris new drug application for fast-acting meloxicam for the treatment of moderate-to-severe acute pain - marketscreener.com

U.S. FDA Accepts Viatris New Drug Application For Fast-Acting Meloxicam For The Treatment Of Moderate-To-Severe Acute Pain - TradingView

Small Cap Opportunities Trust's Viatris Inc(VTRS) Holding History - GuruFocus

FDA accepts Viatris application for fast-acting meloxicam By Investing.com - Investing.com Nigeria

FDA accepts Viatris application for fast-acting meloxicam - Investing.com

Viatris Inc Azioni (VTRS) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a VTRS